Editas Medicine (EDIT) Capital Expenditures Growth (5y) (2020 - 2025)
Powered by 
Analysis
Editas Medicine (EDIT) Capital Expenditures Growth (5y) (2020 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -14.88% |
| Mar 31, 2025 | -19.88% |
| Dec 31, 2024 | -20.41% |
| Sep 30, 2024 | 5.41% |
| Jun 30, 2024 | 18.22% |
| Mar 31, 2024 | 21.11% |
| Dec 31, 2023 | -1.58% |
| Sep 30, 2023 | -23.93% |
| Jun 30, 2023 | -0.83% |
| Mar 31, 2023 | 12.72% |
| Sep 30, 2022 | -19.08% |
| Jun 30, 2022 | -9.09% |
| Mar 31, 2022 | 27.93% |
| Dec 31, 2021 | 33.30% |
| Sep 30, 2021 | -14.20% |
| Jun 30, 2021 | 101.79% |
| Mar 31, 2021 | 23.59% |
| Dec 31, 2020 | 27.97% |
| Sep 30, 2020 | 56.66% |
| Jun 30, 2020 | 28.04% |